Advanced search
Publication Cover
The Journal of Maternal-Fetal & Neonatal Medicine Volume 31, 2018 - Issue 16
Submit an article Journal homepage
179
Views
2
CrossRef citations to date
0
Altmetric
Original Article

The lack of association between vascular endothelial growth factor and retinopathy of prematurity in an observational study

Yogavijayan KandasamyDepartment of Neonatology, The Townsville Hospital, Douglas, Australia; ;Mothers and Babies Research Centre, Hunter Region Mail Centre, Hunter Medical Research Institute, John Hunter Hospital, Newcastle, Australia; ;College of Public Health, Medical and Veterinary Sciences, James Cook University, Douglas, Australia; Correspondence[email protected]
View further author information
,
Leo HartleyDepartment of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, AustraliaView further author information
,
Donna RuddCollege of Public Health, Medical and Veterinary Sciences, James Cook University, Douglas, Australia; View further author information
&
Roger SmithMothers and Babies Research Centre, Hunter Region Mail Centre, Hunter Medical Research Institute, John Hunter Hospital, Newcastle, Australia; View further author information
Pages 2202-2208 | Received 09 Feb 2017, Accepted 31 May 2017, Published online: 20 Jun 2017

References

  • Lawn JE, Kinney MV, Belizan JM, et al. Born too soon: accelerating actions for prevention and care of 15 million newborns born too soon. Reprod Health. 2013;10:S6.
  • Kong L, Fry M, Al-Samarraie M, et al. An update on progress and the changing epidemiology of causes of childhood blindness worldwide. J AAPOS. 2012;16:501–507.
  • Blencowe H, Lawn JE, Vazquez T, et al. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74:35–49.
  • Reynolds JD. Insights in ROP. Am Orthopt J. 2014;64:43–53.
  • Hartnett ME. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity. Clin Perinatol. 2014;41:925–943.
  • Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology. 2015;122:200–210.
  • Ramakrishnan S, Anand V, Roy S. Vascular endothelial growth factor signaling in hypoxia and Inflammation. J Neuroimmune Pharmacol. 2014;9:142–160.
  • Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676.
  • Ho VC, Fong GH. Vasculogenesis and angiogenesis in VEGF receptor-1 deficient mice. Methods Mol Biol. 2015;1332:161–176.
  • Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990;5:519–524.
  • Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684–1694.
  • Klufas MA, Chan RV. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years. J Pediatr Ophthalmol Strabismus. 2015;52:77–84.
  • Kandasamy Y, Hartley L, Rudd D, et al. The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review. Br J Ophthalmol. 2017;101:21–24.
  • Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. Efficacy of intravitreal bevacizumab for Stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–615.
  • Wu WC, Lien R, Liao PJ, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 2015;133:391–397.
  • D’Agostino RB, Belanger A, D’Agostino RB Jr. A suggestion for using powerful and informative tests of normality. Am Stat. 1990;44:316–321.
  • Borras D, Perales-Puchalt A, Ruiz Sacedón N, et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated with intrauterine growth restriction. J Obstet Gynaecol. 2014;34:218–220.
  • Wallner W, Sengenberger R, Strick R, et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci. 2007;112:51–57.
  • Morin J, Luu TM, Superstein R, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137. DOI:10.1542/peds.2015-3218
  • Pertl L, Steinwender G, Mayer C, et al. A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One. 2015;10:e0129383.
  • Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina (Philadelphia, PA). 2015;35:675–680.
  • Maeshima Y, Makino H. Angiogenesis and chronic kidney disease. Fibrogenesis Tissue Repair. 2010;3:13.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.